Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: An antimicrobial stewardship approach at the detroit medical center

Clinical Infectious Diseases

Volumn 59, Issue , 2014, Pages S388-S393

  Pogue, Jason M ^a   Neelakanta, Anupama ^a   Mynatt, Ryan P ^b   Sharma, Sarit ^a   Lephart, Paul ^a,c   Kaye, Keith S ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c DETROIT MEDICAL CENTER   (United States)

Author keywords

A. baumannii; Colistin; Minocycline; Multidrug resistant; Tetracycline

Indexed keywords

CARBAPENEM; DOXYCYCLINE; MINOCYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG FORMULARY; EVALUATION STUDY; EXPERIENCE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MEDICAL DECISION MAKING; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; ADULT; AGED; DRUG EFFECTS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL PHARMACY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MIDDLE AGED; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICHIGAN; MIDDLE AGED; MINOCYCLINE; PHARMACY SERVICE, HOSPITAL;

EID: 84923369038     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu594     Document Type: Article

References (22)

1. Reddy T, Chopra T, Marchaim D, et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 2010; 54:2235-8.
2. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
3. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
4. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50:2946-50.
5. Meletis G, Tzampaz E, Sianou E, et al. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011; 66:946-7.
6. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57:524-31.
7. Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria tested worldwide (2011). Diagn Microbiol Infect Dis 2013; 76:217-21.
8. Wyeth Pharmaceuticals Inc. Tygacil (tigecycline) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2010.
9. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128-31.
10. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-Acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140-51.
11. Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient specific response determinants in patients with hospital-Acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 2012; 56:1065-72.
12. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55:5893-9.
13. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009; 9:26.
14. Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-Analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60:247-57.
15. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilatorassociated pneumonia. J Intensive Care Med 2010; 25:343-8.
16. Wood GC, Hanes SD, Boucher BA, et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-Associated pneumonia. Intensive Care Med 2003; 29:2072-6.
17. Akers KS, Mende K, Yun HC, et al. Tetracycline susceptibility testing and resistance genes in isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex from a U.S. military hospital. Antimicrob Agents Chemother 2009; 53:2693-95.
18. Rempex Pharmaceuticals, Inc. Minocin (minocycline for injection) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2010.
19. Minocycline." In DRUGDEX System. Intranet database, version 5.1. Thomson Healthcare.
20. Etest package supplement. Available at: http://www.mybiomerieux.com. Accessed 5 February 2014.
21. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute, 2013.
22. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-Associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-84.